Lisata Therapeutics Stock Performance
| LSTA Stock | USD 2.82 0.02 0.70% |
The company secures a Beta (Market Risk) of 0.6, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Lisata Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Lisata Therapeutics is expected to be smaller as well. At this point, Lisata Therapeutics has a negative expected return of -0.0386%. Please make sure to verify Lisata Therapeutics' expected short fall, and the relationship between the value at risk and daily balance of power , to decide if Lisata Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lisata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Lisata Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (1.72) | Five Day Return (1.38) | Year To Date Return 2.52 | Ten Year Return (99.52) | All Time Return (100.00) |
Last Split Factor 1:15 | Last Split Date 2022-09-15 |
1 | Castle Biosciences Inc Trading 3.24 percent Higher on Oct 29 | 10/29/2024 |
2 | Cytek Biosciences, Inc. Q3 Earnings and Revenues Beat Estimates | 11/05/2024 |
3 | Artelo Biosciences Stock Dips Amidst Financial Report | 11/13/2024 |
4 | Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit | 11/18/2024 |
5 | Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons Research Through Development of Next Generation Biomarker As... | 11/19/2024 |
6 | Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ... | 11/20/2024 |
7 | The Dr. James Morales Grant for Medicine and Biosciences Invites Undergraduate Scholars to Apply | 11/21/2024 |
8 | Anixa Biosciences board approves purchase of Bitcoin as treasury reserve asset | 11/22/2024 |
9 | Aptose Biosciences Inc. Announces Closing of 8 Million Public Offering | 11/25/2024 |
| Begin Period Cash Flow | 32.2 M | |
| Free Cash Flow | -20 M |
Lisata |
Lisata Therapeutics Relative Risk vs. Return Landscape
If you would invest 300.00 in Lisata Therapeutics on August 29, 2024 and sell it today you would lose (18.00) from holding Lisata Therapeutics or give up 6.0% of portfolio value over 90 days. Lisata Therapeutics is currently does not generate positive expected returns and assumes 3.4623% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Lisata, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lisata Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lisata Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lisata Therapeutics, and traders can use it to determine the average amount a Lisata Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0111
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LSTA |
Estimated Market Risk
| 3.46 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lisata Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lisata Therapeutics by adding Lisata Therapeutics to a well-diversified portfolio.
Lisata Therapeutics Fundamentals Growth
Lisata Stock prices reflect investors' perceptions of the future prospects and financial health of Lisata Therapeutics, and Lisata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lisata Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (11.83 M) | ||||
| Shares Outstanding | 8.39 M | ||||
| Price To Book | 0.71 X | ||||
| EBITDA | (25.52 M) | ||||
| Net Income | (20.84 M) | ||||
| Cash And Equivalents | 72.99 M | ||||
| Cash Per Share | 18.07 X | ||||
| Total Debt | 305 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.33 X | ||||
| Book Value Per Share | 5.91 X | ||||
| Cash Flow From Operations | (20.03 M) | ||||
| Earnings Per Share | (2.51) X | ||||
| Market Capitalization | 23.84 M | ||||
| Total Asset | 54.69 M | ||||
| Retained Earnings | (528.08 M) | ||||
| Working Capital | 47.33 M | ||||
About Lisata Therapeutics Performance
By analyzing Lisata Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Lisata Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Lisata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Lisata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.4 K | 4.6 K | |
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | (0.43) | (0.45) |
Things to note about Lisata Therapeutics performance evaluation
Checking the ongoing alerts about Lisata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lisata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lisata Therapeutics generated a negative expected return over the last 90 days | |
| Lisata Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (20.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Lisata Therapeutics currently holds about 72.99 M in cash with (20.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 19.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from globenewswire.com: Aptose Biosciences Inc. Announces Closing of 8 Million Public Offering |
- Analyzing Lisata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lisata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Lisata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lisata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lisata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lisata Therapeutics' stock. These opinions can provide insight into Lisata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |